Screener
Acadia Pharmaceuticals ACAD Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's total liabilities?
- Acadia Pharmaceuticals (ACAD) reported total liabilities of $436.29M in Q2 2026.
- How has Acadia Pharmaceuticals's total liabilities changed year-over-year?
- Acadia Pharmaceuticals's total liabilities increased by 8.2% year-over-year, from $403.17M to $436.29M.
- What is the long-term trend for Acadia Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's total liabilities has grown at a 16.7% compound annual growth rate (CAGR), from $155.61M to $336.81M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Acadia Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude